Article
Prognostic Risk Refinement using Artificial Intelligence in HR+/HER2- Early Breast Cancer: Implications for CDK4/6 Eligibility Criteria
2026-01-25
Abstract excerpt
Patient selection and enrolment into phase III randomized clinical trials (RCTs) of adjuvant cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapies depend on accurate risk definition. However, standard clinicopathologic criteria incompletely capture recurrence risk, limiting their efficacy in treatment selection. To assess whether artificial intelligence (AI)-enhanced prognostication may enrich the clinical...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1e55ee56-0108-54b6-971e-f5fe64323981
- DOI
- 10.64898/2026.01.23.26344621
